



Elephantiasic Graves' Dermopathy in a Patient with Negative Thyroid-Receptor Auto-Antibodies

Agnethe Berglund, Jette Lindorff Riis¹, Niels Henrik Vinther Krarup², Eva Spaun³, Eva Ebbelhøj

Departments of Endocrinology and Internal Medicine, ¹Dermatology, ²Cardiology, and ³Pathology, Aarhus University Hospital, Aarhus, Denmark

Dear Editor:

A 64-year-old man presented with elephantiasic skin changes of the lower extremities evolved over a period of minimum 10 years. He was obese (body mass index, 34.6 kg/m²) but had no significant co-morbidities.

The skin changes were localized on the dorsal sides of the feet, on the crurae as well as on the left femur (Fig. 1), and consisted of pachydermal hyperkeratosis and a characteristic cobblestone appearance with malodourous scattered impetiginized crusted wounds and fissures. Clinically, the skin changes were compatible with the elephantiasic form of Graves' dermopathy (GD). A deep skin biopsy showed substantial fibrosis, edema, and a slightly increased amount

of mucin in both papillary and reticular dermis. However, the mucin was mainly located in reticular dermis (Fig. 2). There were no lymphatic proliferation or other signs of lymphangiomatosis. Histopathologically, a diagnosis of GD was neither rejected, nor confirmed, due to the massive edema and fibrosing tissue. Subclinical hyperthyroidism was present (thyroid-stimulating-hormone < 0.0014 (reference, 0.30 ~ 4.50) 10⁻³ ie/L, thyroxine = 108 (reference, 60 ~ 140) nmol/L, and triiodothyronine = 1.26 (reference, 1.10 ~ 2.50) nmol/L). Thyroid-receptor-antibodies (TRAb) were negative. An ultrasound examination of the thyroid showed a multinodular goiter. A computed tomography-scan of thorax and abdomen rejected internal disease and ve-



Fig. 1. (A~C) Elephantiasic skin changes on the dorsal sides of the feet and legs consisting of pachydermal hyperkeratosis and a papillomatous cobblestone appearance with malodourous scattered impetiginized crusted wounds and fissures.

Received December 14, 2016, Revised March 6, 2017, Accepted for publication March 10, 2017

Corresponding author: Agnetha Berglund, Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Nørrebrogade 44, DK-8000 Aarhus, Denmark. Tel: 45-78-45-00-00, Fax: 45-78-46-20-10, E-mail: agnetha.berglund@dadlnet.dk

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Copyright © The Korean Dermatological Association and The Korean Society for Investigative Dermatology




Fig. 2. Histopathology. (A) Punch biopsy from lower leg, showing papillary epidermal hyperplasia, slight inconspicuous vascular proliferation and edema (H&E, $\times 20$). (B) Higher magnification. Inconspicuous vascular pattern (H&E, $\times 40$). (C) Increased amount of mucin in papillary and reticular dermis (Colloidal iron stain, $\times 20$). (D) Higher magnification showing the distribution of mucin in dermis (Colloidal iron stain, $\times 100$).

nous obstruction. There was no history of leg trauma, former thyroid disease, previous risk of lymphatic filariasis infection, nor presence of eosinophilia.

Betamethasone with clioquinol and sodium permanganate water combined with extensive compressive therapy including intermittent pneumatic compression only improved skin changes marginally. Euthyroidism was achieved treating with thiamazole.

GD present in approximately 1,5% of patients with Graves' disease and is characterized by localized thickening of the skin, typically in the pretibial area. The pathogenesis is complex and not fully understood. However, immunologic, cellular, molecular, environmental, and mechanical factors are believed being involved. Among these, an autoimmune process stimulated by TRAb is considered the main factor^{1,2}. The skin changes are caused by an increased fibroblast synthesis of mucin accumulating in primarily the papillary and reticular dermis with subsequent edema due to fluid retention. In severe cases, the lymphatic microcirculation may obstruct leading to additional lymphedema and development of elephantiasis². Graves' ophthalmopathy is typically concomitantly present².

GD is associated with positive TRAb and must be ques-

tioned in the absence hereof¹. However, cases of TRAb negative GD have been reported^{3,4}.

Heart failure, nephrotic syndrome, obesity, lymphangiomatosis, cancer or venous obstruction subsequent to surgery can cause lymphedema and skin changes clinically compatible with GD⁵. Except of obesity, none of these were present in this patient and this combined with: 1) the classic clinical skin changes, 2) the histopathological findings compatible with GD, albeit masked by the chronicity of the condition, and 3) the patient's neglect for several years making a previous undiagnosed Graves' disease likely, the clinical picture of this patient was in keeping with elephantiasic GD.

Thus, in conclusion, we present a case of a TRAb negative GD progressed to an extreme elephantiasic form. Clinicians should consider GD as a differential diagnosis in patients with skin changes clinically compatible with GD even though TRAb are undetectable and ophthalmopathy is absent.

ACKNOWLEDGMENT

The patient is sincerely thanked for giving consent to the publication of this report. Photographer Kristian Bang is

thanked for taking the pictures presented.

CONFLICTS OF INTEREST

The authors have nothing to disclose.

REFERENCES

1. Fatourechi V. Thyroid dermopathy and acropachy. *Best Pract Res Clin Endocrinol Metab* 2012;26:553-565.
2. Bartalena L, Fatourechi V. Extrathyroidal manifestations of Graves' disease: a 2014 update. *J Endocrinol Invest* 2014; 37:691-700.
3. Chen JJ, Ladenson PW. Euthyroid pretibial myxedema. *Am J Med* 1987;82:318-320.
4. Verma S, Rongioletti F, Braun-Falco M, Ruzicka T. Preradial myxedema in a euthyroid male: a distinct rarity. *Dermatol Online J* 2013;19:9.
5. Mortimer PS. The pathophysiology of lymphedema. *Cancer* 1998;83(12 Suppl American):2798-2802.